2023 World Conference on Lung Cancer (Posters)-P2.01. Initial Result of the ImmunoPET Phase1 Study: Characterising PD-L1 During Chemoradiotherapy with 89Zr- Durvalumab (MEDI4736) PET/CT

P2.01. Initial Result of the ImmunoPET Phase1 Study: Characterising PD-L1 During Chemoradiotherapy with 89Zr- Durvalumab (MEDI4736) PET/CT - PDF(Slides)

Back to course

Pdf Summary

The study, called ImmunoPET, investigates the use of 89Zr-durvalumab PET/CT to assess the expression of PD-L1 in non-small cell lung cancer (NSCLC) patients undergoing chemo-radiotherapy. The initial results from the first 5 patients participating in the study are presented. The study aims to recruit 20 NSCLC patients eligible for curative-intent concurrent chemo-radiotherapy. Eligible patients include those with ECOG 0-1 NSCLC, regardless of PD-L1 and EGFR, ALK or ROS mutation status. The patients undergo 89Zr-durvalumab and FDG PET/CT before, during, and after radiotherapy, as well as liquid biopsy and selected patients undergo sequential EBUS tissue sampling.<br /><br />The results of the first 5 patients showed a range of PD-L1 expression levels and various characteristics such as age, gender, histology, and TNM stage. The 89Zr-durvalumab PET/CT imaging demonstrated PD-L1 uptake in the primary tumor and right hilar nodes in one patient, despite the initial diagnostic biopsy reporting PD-L1 negativity in squamous cell carcinoma. A repeat EBUS biopsy confirmed adenocarcinoma with PD-L1 expression, leading to the initiation of immunotherapy for the patient.<br /><br />The study is investigator-led and sponsored by Peter MacCallum Cancer Centre, with support from AstraZeneca Pty Ltd. and Telix Pty Ltd. The researchers concluded that 89Zr-durvalumab PET can be used to characterize PD-L1 expression in NSCLC. In some patients, there may be a discrepancy between imaging and PD-L1 immunohistochemistry, highlighting the need for repeat biopsy to identify additional PD-L1 positive patients. Further patient recruitment will determine the proportion of patients whose management may be changed by 89Zr-durvalumab PET.<br /><br />This study provides valuable insights into the potential of PD-L1 PET imaging to impact patient management and personalize treatment decisions, particularly in NSCLC patients undergoing chemo-radiotherapy.

Asset Subtitle

Fiona Hegi-Johnson

Meta Tag

Speaker Fiona Hegi-Johnson

Topic Local-Regional NSCLC: Novel Therapies & Trials

Keywords

ImmunoPET

89Zr-durvalumab PET/CT

PD-L1 expression

non-small cell lung cancer

chemo-radiotherapy

ECOG 0-1 NSCLC

EGFR mutation

ALK mutation

ROS mutation

liquid biopsy